Mehran Jalaie

机构：Pfizer (United States)

发表论文 50 篇 · 总被引 1427 次 · h-index 20

代表论文

• Discovery of a Novel Class of Exquisitely Selective Mesenchymal-Epithelial Transition Factor (c-MET) Protein Kinase Inhibitors and Identification of the Clinical Candidate 2-(4-(1-(Quinolin-6-ylmethyl)-1 H -[1,2,3]triazolo[4,5- b ]pyrazin-6-yl)-1 H -pyrazol-1-yl)ethanol (PF-04217903) for the Treatment of Cancer (2012 · Journal of Medicinal Chemistry · 被引 105)
• Discovery of 1-{(3 R ,4 R )-3-[({5-Chloro-2-[(1-methyl-1 H -pyrazol-4-yl)amino]-7 H -pyrrolo[2,3- d ]pyrimidin-4-yl}oxy)methyl]-4-methoxypyrrolidin-1-yl}prop-2-en-1-one (PF-06459988), a Potent, WT Sparing, Irreversible Inhibitor of T790M-Containing EGFR Mutants (2016 · Journal of Medicinal Chemistry · 被引 94)
• CDK4 selective inhibition improves preclinical anti-tumor efficacy and safety (2025 · Cancer Cell · 被引 61)
• Discovery of a Series of Imidazo[4,5- b ]pyridines with Dual Activity at Angiotensin II Type 1 Receptor and Peroxisome Proliferator-Activated Receptor-γ (2011 · Journal of Medicinal Chemistry · 被引 53)
• Rational design of 6-(2,4-diaminopyrimidinyl)-1,4-benzoxazin-3-ones as small molecule renin inhibitors (2007 · Bioorganic & Medicinal Chemistry · 被引 52)
• Discovery of 2-((1H-benzo[d]imidazol-1-yl)methyl)-4H-pyrido[1,2-a]pyrimidin-4-ones as novel PKM2 activators (2013 · Bioorganic & Medicinal Chemistry Letters · 被引 46)